Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    dailyadda
    dailyadda

    Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide

    2 days ago

    CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.

    CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
    Click here to Read More
    Previous Article
    7 Tips To Maintain Strong Skin Barrier And Keep Skin Healthy During Seasonal Changes
    Next Article
    Son Sentenced, Daughter Fined, Brother Caught: Inside The El Mencho Dynasty

    Related Topstory Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment